Clinical Trial Update: Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of modified CD19 CAR T cells with acalabrutinib for relapsed or refractory mantle cell lymphoma, and recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• CD19 CAR T cells

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Status: RECRUITING